O.D. 260, Inc. - References

References

A selection of publications that utilize O.D.260 products.

Jiménez, J.A., Li, X., Zhang, Y-P, Bae, K.H., Mohammadi, Y., Pandya, P., Kao, C., Gardner, T. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Therapy 2010, 17: 180-191

Greco A., Di Benedetto, A, Howard, C.M., Kelly S., Nande R., Dementieva Y., Miranda M., Brunetti A., Salvatore M., Claudio L., Sarkar D., Dent P., Curiel D.T., Fisher P.B., Claudio, P.P. Eradication of therapy-resistant human prostate tumor using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol. Ther. 2010, 18: 295-306.

Panakanti R., Mahato R.I. Bipartite Vector Encoding hVEGF and hIL-1Ra for ex Vivo Transduction into Human Islets. Mol. Pharmaceutics 2009, 6 (1), pp 274–28.

Panakanti R., Mahato R.I. Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm. Res. 2009, 26(3):587-96.

Sarkar D., Fisher P.B. Cancer-targeted viral vectors. US patent application 20080213220.

Sarkar D., Su Z.Z., Park E.S., Vozhilla N., Dent P., Curiel D.T., Fisher P.B. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther. 2008, 15:293-302.

Dixit V., Juliano, R. L. Selective killing of Smad4-negative tumor cells via a designed repressor strategy. Mol. Pharmacol. 2008, 74:289-297.

Li, X., Liu, Y.H., Lee, S.J., Gardner, T.A., Jeng, M.H., Kao, C. Prostate-Restricted Replicative Adenovirus Expressing Human Endostatin-Angiostatin Fusion Gene Exhibiting Dramatic Antitumor Efficacy. Clinical Cancer Research 2008, 14; 291.

Lebedeva I.V., Su Z.Z., Emdad L., Kolomeyer A., Sarkar D., Kitada S., Waxman S., Reed J.C., Fisher P.B. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene. 2007, 26(5):733-44.

Li, X., Liu, Y.H., Zhang, Y.P., Zhang, S., Pu, X., Gardner, T.A., Jeng, M.H., Kao, C. Fas Ligand Delivery by a Prostate-Restricted Replicative Adenovirus Enhances Safety and Antitumor Efficacy. 2007. Clinical Cancer Research. 13; 5463.

Sarkar D., Lebedeva I.V., Su Z.Z., Chatman L., Vozhilla N., Dent P., Curiel D.T., Fisher P.B. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 2007, 67:5434-42.

Abbosh P.H., Li X., Li L., Gardner T.A., Kao C., Nephew K.P. A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. 2007. Cancer Gene Therapy 14, 399-408.

Sarkar D., Su Z-Z., Fisher P.B. Unique conditionally replication competent bipartite adenoviruses - cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy. Cell Cycle. 2006 Jul;5(14):1531-6. Epub 2006 Jul 17. Review.
Trgovcich J., Cebulla C., Zimmerman P., Sedmak D.D. Human Cytomegalovirus Protein pp71 Disrupts Major Histocompatibility Complex Class I Cell Surface Expression. J Virol. 2006; 80(2): 951–963.
McConnell M.J., Danthinne X., Imperiale M.J. Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol. 2006 Jun; 80(11):5361-70.
Li, X., Raikwar, S. P., Liu, Y. H., Lee, S. J., Zhang, Y. P., Zhang, S., Cheng, L., Lee, S. D., Juliar, B. E., Gardner, T. A., Jeng, M. H., and Kao, C. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol Cancer Ther. 2006, 5:676-684.
Lebedeva IV*, Sarkar D.*, Su Z-Z.*, Gopalkrishnan R.V., Athar M., Randolph A., Valerie K., Dent P., Fisher P.B. (*equal contribution) Molecular target-based therapy of pancreatic cancer. Cancer Res. 2006, 66:2403-2413.
Vines A., Cahoon S., Goldberg I., Saxena U., Pillarisetti S. Novel Anti-inflammatory Role for Glycogen Synthase Kinase-3beta in the Inhibition of Tumor Necrosis Factor-{alpha}- and Interleukin-1beta-induced Inflammatory Gene Expression. J Biol Chem. 2006 Jun 23; 281(25):16985-90.
Sarkar D., Su Z-Z., Vozhilla N., Park E.S., Gupta P., Fisher P.B. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA. 2005, 102:14034-14039.
Sarkar D., Su Z-Z., Vozhilla N., Park E.S., Randolph A., Valerie K., Fisher PB. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res. 2005, 65: 9056-9063.
Li, X., Zhang, J., Gao, H., Vieth, E., Bae, K. H., Zhang, Y. P., Lee, S. J., Raikwar, S., Gardner, T. A., Hutchins, G. D., VanderPutten, D., Kao, C., and Jeng, M. H. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Mol Cancer Ther. 2005, 4: 1850-1859.
Li, X., Zhang, Y. P., Kim, H. S., Bae, K. H., Stantz, K. M., Lee, S. J., Jung, C., Jimenez, J. A., Gardner, T. A., Jeng, M. H., and Kao, C. Gene Therapy for Prostate Cancer by Controlling Adenovirus E1a and E4 Gene Expression with PSES Enhancer. Cancer Res. 2005, 65:1941-1951.
Jung C., Kim R.S., Zhang H.J., Lee S.J., Jeng M.H. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004 Dec 15;64(24):9185-92.
Lee, S. J., Zhang, Y., Lee, S. D., Jung, C., Li, X., Kim, H. S., Bae, K. H., Jeng, M. H., Kao, C., and Gardner, T. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004, 10:1051-1058.
Danthinne X. Simultaneous insertion of two expression cassettes into adenovirus vectors. Biotechniques. 2001 Mar; 30(3):612-6, 618-9.
Danthinne X., Imperiale M.J. Production of first generation adenovirus vectors: a review. Gene Ther. 2000 Oct; 7(20):1707-14. Review.
Danthinne X., Werth E. New tools for the generation of E1- and/or E3-substituted adenoviral vectors. Gene Ther. 2000 Jan; 7(1):80-7.
Danthinne X. New vectors for the construction of double recombinant adenoviruses. J Virol Methods. 1999 Aug; 81(1-2):11-20.